Neurogene (NASDAQ:NGNE - Get Free Report) posted its earnings results on Monday. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.05, Zacks reports. The business had revenue of $0.93 million during the quarter.
Neurogene Price Performance
Neurogene stock traded down $0.81 during mid-day trading on Friday, hitting $14.52. 98,611 shares of the company were exchanged, compared to its average volume of 210,041. Neurogene has a 12-month low of $13.47 and a 12-month high of $74.49. The company has a market capitalization of $215.69 million, a P/E ratio of -3.40 and a beta of 1.01. The business's 50 day simple moving average is $16.88 and its two-hundred day simple moving average is $28.76.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on NGNE. HC Wainwright decreased their target price on Neurogene from $55.00 to $50.00 and set a "buy" rating for the company in a research report on Tuesday. William Blair reiterated an "outperform" rating on shares of Neurogene in a research report on Tuesday. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $59.80.
View Our Latest Analysis on Neurogene
Insider Activity
In other news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the sale, the chief financial officer now owns 72,343 shares of the company's stock, valued at $1,225,490.42. The trade was a 5.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.92% of the company's stock.
About Neurogene
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Recommended Stories
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
